06.05.26 -- Biologics Development Insights: Cell Lines, ADCs & Scalable Manufacturing

An overview of manufacturing strategies and scaling options shows how aligned systems, smart planning, and flexible models support biologics from early development to commercialization.

A leading CDMO offers integrated development and manufacturing solutions for mammalian-based biologics, including mAbs, ADCs, and biosimilars, with quality, flexibility, and regulatory compliance.

ADC design choices shape efficacy and selectivity. Hydrophilic modifications are evaluated for their effects on cytotoxic activity, target specificity, and cell viability across multiple tumor models.

Particle counts don’t manage risk. Biologics need particle ID and forensic insight to separate benign artifacts from real threats and guide early decisions.

Pharma and biotech developers rely on adaptable fill‑finish capacity to meet evolving market demands, scale products from clinical to commercial, and respond rapidly to public‑health emergencies.

NGS provides a sensitive method for verifying biological product integrity. This technology replaces traditional, time-consuming assays with comprehensive genomic analysis, ensuring safety.

Leveraging deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.

Assimilate how integrated R&D and manufacturing streamline the journey from discovery to large-scale production, helping teams advance biologics faster and with greater confidence.

Unlock superior performance for peptides and proteins using nanotechnology. Achieve high drug loads for subcutaneous delivery and stable, aerodynamic dry powders for deep-lung inhalation.

Learn about a manufacturing site with over 35 years of expertise in bioconjugation, APIs, excipients, and adjuvants manufacturing that helps clients accelerate drug development programs worldwide.